Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs
From BioCentury This Week · · 35 min
This plays from the publisher's own server. We do not host a copy.
Description
A pair of high profile clinical setbacks has wiped out more than $40 billion in market cap for Novartis, most of which stemmed from the Phase III miss (https://www.biocentury.com/article/660738) of antisense oligonucleotide therapy pelacarsen. On the latest BioCentury This Week podcast, BioCentury's analysts unpack the fallout for Lp(a) as a cardio target and whether issues with the target, modality or treatment setting contributed to the therapy's lack of efficacy. The analysts also review BioCentury's annual big pharma deals analysis (https://www.biocentury.com/article/660691), which found industry's largest players leaning into disruptive platforms such as bispecifics, in vivo CAR Ts, siRNAs, and degraders. In Washington, Steve Usdin reports on most-favored nation drug pricing carve-outs (https://www.biocentury.com/article/660710) and policy pressure on mid-tier biotechs – plus the conspicuous lack of U.S. biotechs coming to the table -- pays tribute to the late Peter Barton Hutt (https://www.biocentury.com/article/660712), the former FDA Chief Counsel who shaped foundational elements of modern FDA law.
View full story: https://www.biocentury.com/article/660746
#CardiovascularDisease #DrugPricing #BiotechMA #ClinicalTrials #FDA
0:00 - Introduction 1:23 - Novartis Phase III Fallout 18:24 - Annual Pharma Deals Analysis 27:42 - MFN Carve-Outs 32:39 - Remembering Peter Barton Hutt
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)